|
Virtual Meetings 2022
Meet The Professor: Optimizing the Management of Chronic Myeloid LeukemiaFor an up-to-date schedule of upcoming sessions in this series, please click here. PARTICIPATING FACULTY
Jorge Cortes, MD Director, Georgia Cancer Center Cecil F Whitaker Jr, MD/GRA Eminent Scholar Chair in Cancer Augusta University Augusta, Georgia Daniel J DeAngelo, MD, PhD Chief, Division of Leukemia Institute Physician Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School Boston, Massachusetts SERIES MODERATOR Neil Love, MD Research To Practice These activities are supported by an educational grant from Novartis. Agenda
MODULE 1: Optimizing front-line management approaches to chronic myeloid leukemia (CML) MODULE 2: Selection and sequencing of treatment after failure of initial tyrosine kinase inhibitor therapy MODULE 3: Agents targeting the BCR-ABL T315I mutation MODULE 4: Management of side effects associated with CML therapies
Target Audience
CE Credit Form American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Cortes — Consulting Agreements: AbbVie Inc, Bio-Path Holdings, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Novartis, Pfizer Inc, Sun Pharmaceutical Industries Ltd; Stock Options/Ownership — Public Ineligible Company: Bio-Path Holdings. Dr DeAngelo — Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Autolus, Blueprint Medicines, Forty Seven Inc, Gilead Sciences Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Blueprint Medicines, GlycoMimetics Inc, Novartis; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc, FibroGen Inc, Mt Sinai MPN Consortium.SURVEY PARTICIPANTS — Michael R Grunwald, MD — Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Blueprint Medicines, Bristol-Myers Squibb Company, Cardinal Health, CTI BioPharma Corp, Daiichi Sankyo Inc, Gamida Cell, Gilead Sciences Inc, Incyte Corporation, Invitae, Karius, Novartis, Ono Pharmaceutical Co Ltd, Pfizer Inc, Premier, Servier Pharmaceuticals LLC, Sierra Oncology, Stemline Therapeutics Inc; Contracted Research: Incyte Corporation, Janssen Biotech Inc; Stock Options/Ownership: Medtronic Inc. Michael J Mauro, MD — Consulting Agreements: Bristol-Myers Squibb Company, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol-Myers Squibb Company, Novartis, Sun Pharma Advanced Research Company (SPARC). Neil P Shah, MD, PhD — Contracted Research: Bristol-Myers Squibb Company; Data and Safety Monitoring Board/Committee: Sierra Oncology. Kendra Sweet, MD — Advisory Committee: Arog Pharmaceuticals Inc, Astellas, BerGenBio ASA, Bristol-Myers Squibb Company, Curis Inc, Gilead Sciences Inc, Mablytics, Novartis, Pfizer Inc; Contracted Research: Incyte Corporation. SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by an educational grant from Novartis. |